Subtopic Deep Dive
miR15 and miR16 in Chronic Lymphocytic Leukemia
Research Guide
What is miR15 and miR16 in Chronic Lymphocytic Leukemia?
miR15 and miR16 are microRNAs located at the 13q14 locus whose frequent deletion and downregulation act as tumor suppressors by targeting BCL2 in chronic lymphocytic leukemia (CLL).
Calin et al. (2002) first identified deletions and downregulation of miR15/16 in 68% of CLL cases, linking them to 13q14 loss (4984 citations). These miRNAs regulate BCL2 expression, promoting apoptosis in leukemic cells. Pekarsky and Croce (2014) detailed their specific role in CLL pathogenesis (179 citations).
Why It Matters
miR15/16 deletions define a favorable-risk CLL subset, guiding watchful waiting over immediate treatment (Hallek, 2017; 274 citations). Restoration of miR15/16 inhibits BCL2, offering therapeutic potential as shown in preclinical models (Pekarsky et al., 2017; 183 citations). Mouse models confirm synteny to human 13q14, validating miR16 loss in CLL-like disease (Raveché et al., 2007; 279 citations).
Key Research Challenges
Restoring miR15/16 Function
Delivery of synthetic miR15/16 mimics faces barriers in CLL cells due to microenvironment protection. Pekarsky et al. (2017) showed BCL2 inhibition but stability remains unresolved. Off-target effects complicate clinical translation.
Prognostic Heterogeneity
13q14 deletions vary in size and impact, affecting miR15/16 expression inconsistently across patients. Calin et al. (2002) noted frequency but not uniform outcomes. Integration with other markers like TP53 needed (Zenz et al., 2008; 277 citations).
Therapy Resistance Links
miR15/16 loss interacts with p53 pathways in resistant CLL subsets. Zenz et al. (2008) linked miR-34a networks to chemotherapy resistance. BCL2 inhibitors show promise but require miRNA co-targeting (Roberts et al., 2021; 179 citations).
Essential Papers
Frequent deletions and down-regulation of micro- RNA genes <i>miR15</i> and <i>miR16</i> at 13q14 in chronic lymphocytic leukemia
George A. Calin, Calin Dan Dumitru, Masayoshi Shimizu et al. · 2002 · Proceedings of the National Academy of Sciences · 5.0K citations
Micro-RNAs ( miR genes) are a large family of highly conserved noncoding genes thought to be involved in temporal and tissue-specific gene regulation. MiRs are transcribed as short hairpin precurso...
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Michael Hallek, Othman Al‐Sawaf · 2021 · American Journal of Hematology · 357 citations
Abstract Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Leukem...
Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice
Elizabeth Raveché, Erica Salerno, Brian J. Scaglione et al. · 2007 · Blood · 279 citations
Abstract New Zealand black (NZB) mice with autoimmune and B lymphoproliferative disease (B-LPD) are a model for human chronic lymphocytic leukemia (CLL). A genomewide linkage scan of the NZB loci a...
miR-34a as part of the resistance network in chronic lymphocytic leukemia
Thorsten Zenz, Julia Mohr, Eric Eldering et al. · 2008 · Blood · 277 citations
Abstract 17p (TP53) deletion identifies patients with chronic lymphocytic leukemia (CLL) who are resistant to chemotherapy. The members of the miR-34 family have been discovered to be direct p53 ta...
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Michael Hallek · 2017 · American Journal of Hematology · 274 citations
Abstract Disease Overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical cour...
Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities
Nicholas Chiorazzi, Manlio Ferrarini · 2010 · Blood · 255 citations
Abstract Several cell types have been suggested as giving rise to chronic lymphocytic leukemia (CLL), and these suggestions have reflected the sophistication of technology available at the time. Al...
BCL2 and miR-15/16: from gene discovery to treatment
Yuri Pekarsky, Veronica Balatti, Carlo M. Croce · 2017 · Cell Death and Differentiation · 183 citations
Reading Guide
Foundational Papers
Start with Calin et al. (2002) for discovery of miR15/16 deletions (4984 citations), then Pekarsky and Croce (2014) for mechanistic role, followed by Raveché et al. (2007) for mouse validation.
Recent Advances
Hallek (2021; 357 citations) updates prognostic role; Pekarsky et al. (2017; 183 citations) covers BCL2 therapy links.
Core Methods
FISH for 13q14 detection, miRNA qPCR, anti-luciferase assays for targets, NZB mouse models.
How PapersFlow Helps You Research miR15 and miR16 in Chronic Lymphocytic Leukemia
Discover & Search
Research Agent uses searchPapers('miR15 miR16 13q14 CLL') to retrieve Calin et al. (2002), then citationGraph to map 4984 citing papers and findSimilarPapers for miRNA therapeutics. exaSearch uncovers NZB mouse models like Raveché et al. (2007).
Analyze & Verify
Analysis Agent applies readPaperContent on Calin et al. (2002) abstracts, verifyResponse with CoVe to confirm 68% deletion rate, and runPythonAnalysis to plot miR15/16 expression vs. BCL2 levels from supplementary data. GRADE grading scores evidence as high for prognostic claims.
Synthesize & Write
Synthesis Agent detects gaps in miR15/16 restoration trials, flags contradictions between mouse (Raveché et al., 2007) and human data. Writing Agent uses latexEditText for methods sections, latexSyncCitations for 13q14 refs, latexCompile for full reviews, and exportMermaid for BCL2-miR regulatory diagrams.
Use Cases
"Extract miR15/16 expression data from CLL cohorts and plot vs survival"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on GEO datasets) → CSV survival curves with p-values.
"Write LaTeX review on miR15/16 BCL2 axis in CLL"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Calin 2002, Pekarsky 2017) → latexCompile → PDF with mermaid pathway diagram.
"Find code for miR15/16 target prediction in CLL papers"
Research Agent → paperExtractUrls (Pekarsky papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable TargetScan pipeline.
Automated Workflows
Deep Research workflow scans 50+ miR15/16 papers via citationGraph from Calin et al. (2002), producing structured reports on 13q14 subtypes. DeepScan's 7-step chain verifies BCL2 regulation with CoVe checkpoints and Python stats on expression data. Theorizer generates hypotheses linking miR15/16 to Hallek (2021) treatment updates.
Frequently Asked Questions
What defines miR15/16 role in CLL?
miR15/16 at 13q14 are deleted in 68% of CLL cases, downregulating BCL2 to promote survival (Calin et al., 2002).
What methods study miR15/16 in CLL?
qPCR for expression, FISH for 13q14 deletions, luciferase assays for BCL2 targeting (Pekarsky and Croce, 2014).
What are key papers on miR15/16 CLL?
Calin et al. (2002; 4984 citations) discovered deletions; Pekarsky et al. (2017; 183 citations) linked to BCL2 therapy.
What open problems exist?
Clinical trials for miR15/16 mimics absent; heterogeneity in 13q14 deletions unexplained (Hallek, 2017).
Research Chronic Lymphocytic Leukemia Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching miR15 and miR16 in Chronic Lymphocytic Leukemia with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.